Cytokinetics, Incorporated (CYTK)
Company Info
| ISIN | US23282W6057 |
|---|---|
| CUSIP | 23282W605 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $6.83B |
|---|---|
| EPS | -$5.45 |
| PEG Ratio | -0.42 |
| Revenue (TTM) | $7.53M |
| Gross Profit (TTM) | -$146.23M |
| EBITDA (TTM) | -$484.31M |
| Year Range | $25.98 - $110.25 |
| Target Price | $95.06 |
| Short % | 21.97% |
| Short Ratio | 5.79 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: CYTK vs. SPY, CYTK vs. SMH, CYTK vs. VOO
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Cytokinetics, Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Cytokinetics, Incorporated had a return of -22.94% year-to-date (YTD) and 63.55% in the last 12 months. Over the past 10 years, Cytokinetics, Incorporated had an annualized return of 30.63%, outperforming the S&P 500 benchmark which had an annualized return of 10.41%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -22.94% | 6.17% |
| 1 month | -9.34% | -2.72% |
| 6 months | 85.74% | 17.29% |
| 1 year | 63.55% | 23.80% |
| 5 years (annualized) | 48.84% | 11.47% |
| 10 years (annualized) | 30.63% | 10.41% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -6.42% | -7.54% | -2.95% | -12.54% | ||||||||
| 2023 | 18.33% | -3.96% | 149.37% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of CYTK is 80, placing it in the top 20% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Cytokinetics, Incorporated(CYTK)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Cytokinetics, Incorporated (CYTK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Cytokinetics, Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cytokinetics, Incorporated was 97.09%, occurring on Oct 10, 2014. Recovery took 2324 trading sessions.
The current Cytokinetics, Incorporated drawdown is 40.46%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.09% | May 6, 2004 | 2627 | Oct 10, 2014 | 2324 | Jan 8, 2024 | 4951 |
| -43.25% | Jan 9, 2024 | 78 | Apr 30, 2024 | — | — | — |
| -1.52% | May 4, 2004 | 1 | May 4, 2004 | 1 | May 5, 2004 | 2 |
Volatility
Volatility Chart
The current Cytokinetics, Incorporated volatility is 11.60%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |